Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8719965 | 0.77 | CA1 (0.33) | CA1CA2CA9 | |
| SCHEMBL28185747 | 0.77 | CA1 (0.33) | CA1CA2CA9 | |
| SCHEMBL17878003 | 0.73 | ACHE (0.42) | — | |
| SCHEMBL8816497 | 0.71 | — | — | |
| SCHEMBL8818287 | 0.71 | — | — | |
| SCHEMBL5015010 | 0.63 | — | — | |
| SCHEMBL557762 | 0.62 | — | — | |
| SCHEMBL10430721 | 0.62 | CA1 (0.41) | CA1CA2CA9 | |
| SCHEMBL809377 | 0.60 | CA1 (0.38) | CA1CA2CA9 | |
| SCHEMBL25834840 | 0.60 | CA1 (0.38) | CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240254158-A1 | METHOD FOR PRODUCING OLIGONUCLEIC ACID COMPOUND | NIPPON SHINYAKU CO., LTD. (JP) | 2024-08-01 | — | — | US | disclosed |
| EP-4332111-A1 | METHOD FOR PRODUCING OLIGONUCLEIC ACID COMPOUND | Nippon Shinyaku Co., Ltd. (JP) | 2024-03-06 | — | — | EP | disclosed |
| CN-115536702-A | Phosphonic acid difluoro alkyl ester methylene oxygen group pentafluoro ring triphosphazene compound and its preparation | 张家港市国泰华荣化工新材料有限公司 | 2022-12-30 | — | — | CN | disclosed |
| WO-2022230954-A1 | METHOD FOR PRODUCING OLIGONUCLEIC ACID COMPOUND | 日本新薬株式会社 | 2022-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240254158-A1 | METHOD FOR PRODUCING OLIGONUCLEIC ACID COMPOUND | POLRMT, CYC1, MRM1 | CA1 332/4885CA2 1030/4885CA9 1275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.